Varian Medical Systems designs, manufactures, sells, and services medical devices and software products for treating cancer and other medical conditions in the United States. The company operates in two segments, Oncology Systems and Imaging Components. The company was founded in 1948 and is based in Palo Alto, California.
VAR Price Forecast Based on DCF Valuation
DCF Fair Value Target:
Below please find a table outlining a discounted cash flow forecast for VAR, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Varian Medical Systems Inc ranked in the 11th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. The most interesting components of our discounted cash flow analysis for Varian Medical Systems Inc ended up being:
Its compound free cash flow growth rate, as measured over the past 5.72 years, is -0.05% -- higher than merely 18.57% of stocks in our DCF forecasting set.
The business' balance sheet suggests that 4% of the company's capital is sourced from debt; this is greater than only 13.22% of the free cash flow producing stocks we're observing.
The company's cost of debt, derived from its interest coverage, tax rate, and market capitalization, is greater than just 0% of stocks in its sector (Healthcare).
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
Want more companies with a valuation profile/forecast similar to that of Varian Medical Systems Inc? See LGND, STAA, PCRX, DYNT, and RGEN.
NEW YORK, Sept. 16, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. reminds investors that it is investigating potential claims on behalf of stockholders of Rosetta Stone Inc. (NYSE: RST), Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), Jernigan Capital, Inc. (NYSE: JCAP), and Varian Medical Systems, Inc. (NYSE: VAR). Additional information about each potential action can be found at the link provided. Rosetta Stone Inc. (NYSE: RST)Buyer: Cambium Learning GroupOn August 31, 2020, Rosetta Stone announced that it had signed an agreement to be acquired by Cambium for approximately $792 million. Pursuant to the merger agreement, Rosetta Stone stockholders will receive $30 in cash for each share of Rosetta Stone common stock owned. The deal is scheduled to close in the fourth quarter ...
NEW YORK, Sept. 16, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU)Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of Immunomedics to Gilead Sciences, Inc. for $88.00 per share in cash. If you are a IMMU investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected] Livongo Health, Inc. (NASDAQ:LVGO)Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of LVGO to Teladoc Health, Inc. for 0.5920x Teladoc shares plus cash consideration of $11.33 per share. If you are a LVGO investor, and would li...
NEW YORK, NY / ACCESSWIRE / September 16, 2020 / Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating: * National General Holdings Corp.
Varian (NYSE: VAR) has received notice from the Customs Tariff Commission of the State Council of China that the first exclusion of the additional tariffs China imposed on US products will expire on September 16, 2020. In accordance with procedures, the exclusion will be extended by one year, from September 17, 2020 to September 16, 2021. Varian medical linear accelerators are one of the first items to be excluded from additional tariffs.